Paxman AB (publ), together with its subsidiaries, develops and sells PAXMAN scalp cooling system for minimizing hair loss in connection with chemotherapy treatment in Europe, North and South America, Central America, Asia, and Oceania. More Details
Worrying balance sheet with weak fundamentals.
Share Price & News
How has Paxman's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PXMB.F has not had significant price volatility in the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: Insufficient data to determine how PXMB.F performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how PXMB.F performed against the US Market.
Price Volatility Vs. Market
How volatile is Paxman's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Paxman undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate PXMB.F's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate PXMB.F's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: PXMB.F is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: PXMB.F is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PXMB.F's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PXMB.F is overvalued based on its PB Ratio (21.1x) compared to the US Medical Equipment industry average (3.7x).
How is Paxman forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Paxman has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of PXMB.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on theOTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Paxman's filings and announcementshere.
- Explore growth companies in the Healthcare industry.
How has Paxman performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: PXMB.F is currently unprofitable.
Growing Profit Margin: PXMB.F is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if PXMB.F's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare PXMB.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PXMB.F is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.8%).
Return on Equity
High ROE: PXMB.F has a negative Return on Equity (-3.85%), as it is currently unprofitable.
How is Paxman's financial position?
Financial Position Analysis
Short Term Liabilities: PXMB.F's short term assets (SEK33.5M) do not cover its short term liabilities (SEK39.8M).
Long Term Liabilities: PXMB.F's short term assets (SEK33.5M) exceed its long term liabilities (SEK21.9M).
Debt to Equity History and Analysis
Debt Level: PXMB.F's debt to equity ratio (174.3%) is considered high.
Reducing Debt: Insufficient data to determine if PXMB.F's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PXMB.F has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: PXMB.F has less than a year of cash runway if free cash flow continues to grow at historical rates of 13.1% each year.
What is Paxman current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PXMB.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PXMB.F's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PXMB.F's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PXMB.F's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PXMB.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Richard Paxman (37 yo)
Mr. Richard Paxman has been the Chief Executive Officer of Paxman AB (publ) since 2013 and has been its Director since February 10, 2017. Mr. Paxman has extensive experience in global market development in ...
CEO Compensation Analysis
Compensation vs Market: Richard's total compensation ($USD0.00) is below average for companies of similar size in the US market ($USD606.89K).
Compensation vs Earnings: Richard's compensation has increased whilst the company is unprofitable.
|CEO & Director||7.67yrs||kr1.64m||8% |
|Independent Chairman of the Board||3.75yrs||kr100.00k||0.62% |
|Independent Director||3.67yrs||kr50.00k||no data|
|Independent Director||3.67yrs||kr50.00k||0.054% |
|Independent Director||3.75yrs||kr50.00k||4.78% |
|Director||3.67yrs||no data||39.15% |
Experienced Board: PXMB.F's board of directors are considered experienced (3.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Paxman AB (publ)'s company bio, employee growth, exchange listings and data sources
- Name: Paxman AB (publ)
- Ticker: PXMB.F
- Exchange: OTCPK
- Founded: 1996
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: kr522.008m
- Listing Market Cap: kr57.159m
- Shares outstanding: 16.01m
- Website: https://www.paxman.se
Number of Employees
- Paxman AB (publ)
- Pirgatan 13
- Blekinge County
- 374 35
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PAX||OM (OMX Nordic Exchange Stockholm)||Yes||Share Capital||SE||SEK||Jun 2017|
|PXMB.F||OTCPK (Pink Sheets LLC)||Yes||Share Capital||US||USD||Jun 2017|
Paxman AB (publ), together with its subsidiaries, develops and sells PAXMAN scalp cooling system for minimizing hair loss in connection with chemotherapy treatment in Europe, North and South America, Centr ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/25 06:15|
|End of Day Share Price||2020/08/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.